Dianthus Therapeutics (DNTH) Competitors $21.82 -0.03 (-0.11%) As of 02:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. MLTX, ALVO, IMVT, HCM, ACAD, APLS, AMRX, RXRX, IBRX, and BHVNShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include MoonLake Immunotherapeutics (MLTX), Alvotech (ALVO), Immunovant (IMVT), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Amneal Pharmaceuticals (AMRX), Recursion Pharmaceuticals (RXRX), ImmunityBio (IBRX), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. MoonLake Immunotherapeutics Alvotech Immunovant HUTCHMED ACADIA Pharmaceuticals Apellis Pharmaceuticals Amneal Pharmaceuticals Recursion Pharmaceuticals ImmunityBio Biohaven MoonLake Immunotherapeutics (NASDAQ:MLTX) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking. Which has higher earnings and valuation, MLTX or DNTH? MoonLake Immunotherapeutics has higher earnings, but lower revenue than Dianthus Therapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$36.01M-$1.89-21.73Dianthus Therapeutics$6.24M112.45-$43.56M-$2.60-8.39 Do analysts recommend MLTX or DNTH? MoonLake Immunotherapeutics presently has a consensus price target of $80.50, suggesting a potential upside of 96.03%. Dianthus Therapeutics has a consensus price target of $54.33, suggesting a potential upside of 148.95%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the media refer more to MLTX or DNTH? In the previous week, MoonLake Immunotherapeutics had 13 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 17 mentions for MoonLake Immunotherapeutics and 4 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.13 beat MoonLake Immunotherapeutics' score of 0.76 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 5 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MLTX or DNTH more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -15.54% -15.09% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Do institutionals & insiders have more ownership in MLTX or DNTH? 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in MLTX or DNTH? MoonLake Immunotherapeutics received 43 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 96.30% of users gave Dianthus Therapeutics an outperform vote while only 82.14% of users gave MoonLake Immunotherapeutics an outperform vote. CompanyUnderperformOutperformMoonLake ImmunotherapeuticsOutperform Votes6982.14% Underperform Votes1517.86%Dianthus TherapeuticsOutperform Votes2696.30% Underperform Votes13.70% Which has more risk & volatility, MLTX or DNTH? MoonLake Immunotherapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. SummaryDianthus Therapeutics beats MoonLake Immunotherapeutics on 10 of the 18 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$701.15M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-8.737.3822.6318.55Price / Sales112.45241.88397.30103.38Price / CashN/A65.8538.1834.62Price / Book1.916.476.704.25Net Income-$43.56M$143.68M$3.23B$248.27M7 Day Performance2.80%1.85%1.36%1.28%1 Month Performance29.68%6.73%3.85%3.75%1 Year Performance-3.13%-2.72%15.87%5.31% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.7382 of 5 stars$21.83-0.1%$54.33+148.9%+2.3%$701.15M$6.24M-8.7380Upcoming EarningsNews CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.5529 of 5 stars$40.00+4.4%$80.50+101.3%+2.9%$2.56BN/A-31.012Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsALVOAlvotech1.7401 of 5 stars$8.33+0.5%$18.00+116.1%-45.9%$2.51B$489.68M-4.504Short Interest ↑IMVTImmunovant2.2237 of 5 stars$14.46-4.6%$41.00+183.5%-41.1%$2.46BN/A-5.52120High Trading VolumeHCMHUTCHMED1.9657 of 5 stars$13.89+0.9%$19.00+36.8%-19.8%$2.42B$630.20M0.001,760Short Interest ↑ACADACADIA Pharmaceuticals4.2586 of 5 stars$14.38-2.4%$23.93+66.4%-12.6%$2.40B$957.80M18.44510Upcoming EarningsAnalyst ForecastPositive NewsAPLSApellis Pharmaceuticals4.1182 of 5 stars$18.03-0.9%$45.35+151.5%-56.5%$2.26B$781.37M-8.88770Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageAMRXAmneal Pharmaceuticals3.3494 of 5 stars$7.13-3.1%$10.80+51.5%+26.6%$2.21B$2.79B-10.497,600News CoveragePositive NewsRXRXRecursion Pharmaceuticals2.213 of 5 stars$5.41-1.6%$8.20+51.6%-28.5%$2.17B$58.49M-3.54400Upcoming EarningsIBRXImmunityBio1.6314 of 5 stars$2.51+1.6%$12.19+385.6%-68.6%$2.14B$14.75M-2.73590Upcoming EarningsAnalyst ForecastBHVNBiohaven3.6265 of 5 stars$20.67+1.5%$62.77+203.7%-43.0%$2.11BN/A-2.21239Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies MoonLake Immunotherapeutics Alternatives Alvotech Alternatives Immunovant Alternatives HUTCHMED Alternatives ACADIA Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives Recursion Pharmaceuticals Alternatives ImmunityBio Alternatives Biohaven Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DNTH Stock Free DNTH Stock Alerts